APF - ~5mM in dimethyl formamide,≥98%, high purity , CAS No.359010-70-1

  • ≥95%
  • ~5mM in dimethyl formamide
Item Number
A356800
Grouped product items
SKUSizeAvailabilityPrice Qty
A356800-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,185.90

a fluorescent reagent used to detect highly reactive oxygen species

Basic Description

Synonyms2-[3-(4-aminophenoxy)-6-oxoxanthen-9-yl]benzoic acid | DTXSID40469879 | 2-(6-(4-Aminophenoxy)-3-oxo-3H-xanthen-9-yl)benzoic acid | SCHEMBL1968894 | 2-[6-(4-AMINOPHENOXY)-3-OXO-3H-XANTHEN-9-YL]BENZOIC ACID | 2-[6-(4-Aminophenoxy)-3-oxo-3H-xanthen-9-yl]-ben
Specifications & Purity≥95%, ~5mM in dimethyl formamide
Storage TempStore at 2-8°C
Shipped InWet ice
Product Description

APF is a fluorescent reagent (λ|Ex|max|: 490nm; λ|Em|max|: 515nm) used in the detection of highly reactive oxygen species (hROS). Immediately reacts with hROS such as hydroxyl radical, peroxynitrite and hypochlorite, and the fluorescence intensity greatly increases. When using APF together with HPF, it also allows for specific detection of hypochlorite (|-|OCl) to elucidate reliable roles of|-|OCl in biological systems such as netrophils. Peroxynitrite can also be detected in distinction from nitric oxide and superoxide since APF does not react with nitric oxide, superoxide and hydrogen peroxide. APF is resistant to light-induced autooxidation

AI Insight

Product Properties

Excitation and Emision Rangesλex 490 nm, λem 515 nm

Names and Identifiers

IUPAC Name 2-[3-(4-aminophenoxy)-6-oxoxanthen-9-yl]benzoic acid
INCHI InChI=1S/C26H17NO5/c27-15-5-8-17(9-6-15)31-18-10-12-22-24(14-18)32-23-13-16(28)7-11-21(23)25(22)19-3-1-2-4-20(19)26(29)30/h1-14H,27H2,(H,29,30)
InChi Key GIERQYKZWFLVGR-UHFFFAOYSA-N
Canonical SMILES C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)OC5=CC=C(C=C5)N)C(=O)O
Isomeric SMILES C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)OC5=CC=C(C=C5)N)C(=O)O
PubChem CID 11640420
Molecular Weight 423.42

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Related Documents

Reviews

Customer Reviews

Citations of This Product

1. Guoting Su, Hui Xu, FangFang Zhou, Xiyu Gong, Songwen Tan, Yongju He.  (2023)  Boosting Reactive Oxygen Species Generation with a Dual-Catalytic Nanomedicine for Enhanced Tumor Nanocatalytic Therapy.  ACS Applied Materials & Interfaces,  15  (51): (59175–59188).  [PMID:38095444] [10.1021/acsami.3c13882]
2. Xingyu Fan, Xiyu Gong, Fangfang Zhou, Botao Chen, Songwen Tan, Hui Xu, Anqiang Pan, Shuquan Liang, Yongju He.  (2022)  Mesoporous peroxidase nanozyme for synergistic chemodynamic therapy and chemotherapy.  COLLOIDS AND SURFACES B-BIOINTERFACES,  216  (112603).  [PMID:35653958] [10.1016/j.colsurfb.2022.112603]
3. Linjie Shao, Taishun Hu, Xingyu Fan, Xiaozan Wu, Fangfang Zhou, Botao Chen, Songwen Tan, Hui Xu, Anqiang Pan, Shuquan Liang, Yongju He.  (2022)  Intelligent Nanoplatform with Multi Therapeutic Modalities for Synergistic Cancer Therapy.  ACS Applied Materials & Interfaces,  14  (11): (13122–13135).  [PMID:35286061] [10.1021/acsami.2c01913]
4. Li Cong, Lai Chaoyang, Qiu Qiujun, Luo Xiang, Hu Ling, Zheng Huangliang, Lu Yi, Liu Min, Zhang Hongxia, Liu Xinrong, Deng Yihui, Song Yanzhi.  (2019)  Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy.  AAPS PHARMSCITECH,  20  (5): (1-13).  [PMID:31093777] [10.1208/s12249-019-1385-0]
5. Chaoyang Lai, Cong Li, Mengyang Liu, Qiujun Qiu, Xiang Luo, Xinrong Liu, Ling Hu, Yihui Deng, Yanzhi Song.  (2019)  Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes.  Asian Journal of Pharmaceutical Sciences,  14  (455).  [PMID:32104474] [10.1016/j.ajps.2018.07.004]
6. Chaoyang Lai, Cong Li, Xiang Luo, Mengyang Liu, Xinrong Liu, Ling Hu, Le Kang, Qiujun Qiu, Yihui Deng, Yanzhi Song.  (2018)  Use of Dual-Ligand Modification in Kupffer Cell-Targeted Liposomes To Examine the Contribution of Kupffer Cells to Accelerated Blood Clearance Phenomenon.  MOLECULAR PHARMACEUTICS,  15  (7): (2548–2558).  [PMID:29768009] [10.1021/acs.molpharmaceut.8b00042]

References

1. Guoting Su, Hui Xu, FangFang Zhou, Xiyu Gong, Songwen Tan, Yongju He.  (2023)  Boosting Reactive Oxygen Species Generation with a Dual-Catalytic Nanomedicine for Enhanced Tumor Nanocatalytic Therapy.  ACS Applied Materials & Interfaces,  15  (51): (59175–59188).  [PMID:38095444] [10.1021/acsami.3c13882]
2. Xingyu Fan, Xiyu Gong, Fangfang Zhou, Botao Chen, Songwen Tan, Hui Xu, Anqiang Pan, Shuquan Liang, Yongju He.  (2022)  Mesoporous peroxidase nanozyme for synergistic chemodynamic therapy and chemotherapy.  COLLOIDS AND SURFACES B-BIOINTERFACES,  216  (112603).  [PMID:35653958] [10.1016/j.colsurfb.2022.112603]
3. Linjie Shao, Taishun Hu, Xingyu Fan, Xiaozan Wu, Fangfang Zhou, Botao Chen, Songwen Tan, Hui Xu, Anqiang Pan, Shuquan Liang, Yongju He.  (2022)  Intelligent Nanoplatform with Multi Therapeutic Modalities for Synergistic Cancer Therapy.  ACS Applied Materials & Interfaces,  14  (11): (13122–13135).  [PMID:35286061] [10.1021/acsami.2c01913]
4. Li Cong, Lai Chaoyang, Qiu Qiujun, Luo Xiang, Hu Ling, Zheng Huangliang, Lu Yi, Liu Min, Zhang Hongxia, Liu Xinrong, Deng Yihui, Song Yanzhi.  (2019)  Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy.  AAPS PHARMSCITECH,  20  (5): (1-13).  [PMID:31093777] [10.1208/s12249-019-1385-0]
5. Chaoyang Lai, Cong Li, Mengyang Liu, Qiujun Qiu, Xiang Luo, Xinrong Liu, Ling Hu, Yihui Deng, Yanzhi Song.  (2019)  Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes.  Asian Journal of Pharmaceutical Sciences,  14  (455).  [PMID:32104474] [10.1016/j.ajps.2018.07.004]
6. Chaoyang Lai, Cong Li, Xiang Luo, Mengyang Liu, Xinrong Liu, Ling Hu, Le Kang, Qiujun Qiu, Yihui Deng, Yanzhi Song.  (2018)  Use of Dual-Ligand Modification in Kupffer Cell-Targeted Liposomes To Examine the Contribution of Kupffer Cells to Accelerated Blood Clearance Phenomenon.  MOLECULAR PHARMACEUTICS,  15  (7): (2548–2558).  [PMID:29768009] [10.1021/acs.molpharmaceut.8b00042]

Solution Calculators